# OnCo record irinotecan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/irinotecan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "irinotecan" ;
  schema:name "Irinotecan (and liposomal irinotecan)"@en ;
  schema:description "Irinotecan is a topoisomerase-blocking chemotherapy central to bowel and pancreatic cancer regimens (FOLFIRI, FOLFIRINOX, NALIRIFOX) and to salvage therapy in childhood sarcomas; it carries the same warhead as the deruxtecan ADC payloads."@en ;
  schema:url <https://onco.cc/drugs/irinotecan/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Irinotecan> ;
  owl:sameAs <http://www.wikidata.org/entity/Q412197> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=irinotecan> ;
  onco:status "approved" ;
  onco:tag "gap-fill", "generic", "who-essential" ;
  onco:modality "Topoisomerase I inhibitor (camptothecin prodrug)" ;
  schema:alternateName "Camptosar / Onivyde" ;
  onco:approval "US 1996: Metastatic colorectal cancer after 5-FU; first line with 5-FU/LV 2000", "US 2015: Liposomal irinotecan with 5-FU/LV in metastatic pancreatic cancer after gemcitabine", "US 2024: Liposomal irinotecan in NALIRIFOX first-line metastatic pancreatic cancer" ;
  onco:acceleratedApproval "US 1996-06-14: Metastatic colon or rectal carcinoma that progressed following 5-FU therapy" ;
  onco:acceleratedApprovalConfirmed "US 1998-10-22: Metastatic colon or rectal carcinoma that progressed following 5-FU therapy" ;
  onco:related <https://onco.cc/technologies/st-johns-wort-interaction/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/ewing-sarcoma/>, <https://onco.cc/cancers/rhabdomyosarcoma/>, <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/medulloblastoma/> ;
  onco:technologies <https://onco.cc/technologies/topoisomerase-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:companies <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/ipsen/>, <https://onco.cc/companies/merrimack-pharmaceuticals/> ;
  onco:terms <https://onco.cc/terms/payload/> ;
  onco:trials <https://onco.cc/trials/nct06219941/>, <https://onco.cc/trials/nct04657068/>, <https://onco.cc/trials/nct05592626/>, <https://onco.cc/trials/nct07356973/>, <https://onco.cc/trials/nct04725994/>, <https://onco.cc/trials/swog-s1406/>, <https://onco.cc/trials/avf2107g/> .